Medical News Today (MNT)New Screening Tool May Detect More Dangerous Prostate Cancers Than PSA Testing Alone

⚠️ Practice-Changing Potential

PSA screening remains widely used but has well-known limitations, including false positives leading to unnecessary biopsies, as well as missed aggressive cancers at lower PSA levels. Risk-based screening models aim to improve detection accuracy without increasing harm.

Clinical Considerations

• Stockholm3 detected 90% of significant cancers vs 74% with PSA ≥3 ng/mL
• PSA ≥4 ng/mL detected only ~52% of significant cancers
• Specificity remained similar, avoiding excess false positives
• Combines PSA, genetic markers, protein biomarkers, and clinical variables
• May reduce unnecessary procedures (~45% fewer biopsies)
• Follow-up limited to 2 years

Practice Applications

• PSA alone is insufficient for risk stratification
• Multivariable models may improve biopsy selection and MRI triage pathways
• Expected future pathway is risk model → MRI → biopsy
• Adoption depends on long-term outcomes and implementation feasibility